The global Antibiotic Resistant Infection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.

An antibiotic-resistant infection refers to a bacterial or fungal infection that does not respond to standard antibiotic or antifungal treatments that would typically be effective against the causative microorganism. This resistance occurs when bacteria or fungi develop mechanisms to evade the effects of antibiotics or antifungals, often due to genetic mutations or acquiring resistance genes from other organisms. Antibiotic-resistant infections pose significant challenges in healthcare settings, as they can lead to prolonged illness, increased mortality rates, and higher healthcare costs. Managing these infections requires alternative treatment strategies, such as using different classes of antibiotics, combination therapies, or non-antibiotic approaches, and emphasizes the importance of infection control measures to prevent their spread.

From a downstream perspective, Hospital Pharmacies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Antibiotic Resistant Infection leading manufacturers including Pfizer, Johnson & Johnson, Merck & Co., Inc., GSK, Roche, AbbVie, AstraZeneca, Bayer AG, Teva Pharmaceutical, Sanofi, etc., dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Antibiotic Resistant Infection market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Antibiotic Resistant Infection Market Report

Report Metric	Details
Report Name	Antibiotic Resistant Infection Market
Segment by Type	Oral Parenteral
Segment by Application	Hospital Pharmacies Retail Pharmacies Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Johnson & Johnson, Merck & Co., Inc., GSK, Roche, AbbVie, AstraZeneca, Bayer AG, Teva Pharmaceutical, Sanofi, Novartis, Lupin, Advacare Pharma, Validus Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Antibiotic Resistant Infection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Antibiotic Resistant Infection Market report?

Ans: The main players in the Antibiotic Resistant Infection Market are Pfizer, Johnson & Johnson, Merck & Co., Inc., GSK, Roche, AbbVie, AstraZeneca, Bayer AG, Teva Pharmaceutical, Sanofi, Novartis, Lupin, Advacare Pharma, Validus Pharmaceuticals

What are the Application segmentation covered in the Antibiotic Resistant Infection Market report?

Ans: The Applications covered in the Antibiotic Resistant Infection Market report are Hospital Pharmacies, Retail Pharmacies, Other

What are the Type segmentation covered in the Antibiotic Resistant Infection Market report?

Ans: The Types covered in the Antibiotic Resistant Infection Market report are Oral, Parenteral

1 Study Coverage

1.1 Introduction to Antibiotic Resistant Infection: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Antibiotic Resistant Infection Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Oral

1.2.3 Parenteral

1.3 Market Segmentation by Application

1.3.1 Global Antibiotic Resistant Infection Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Antibiotic Resistant Infection Revenue Estimates and Forecasts 2020-2031

2.2 Global Antibiotic Resistant Infection Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020-2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

3.1 Global Antibiotic Resistant Infection Player Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2020-2025)

3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Player (2020 VS 2024)

3.2 Global Antibiotic Resistant Infection Companies Headquarters and Service Footprint

3.3 Main Product Type Market Size by Players

3.3.1 Oral Market Size by Players

3.3.2 Parenteral Market Size by Players

3.4 Global Antibiotic Resistant Infection Market Concentration and Dynamics

3.4.1 Global Market Concentration (CR5 and HHI)

3.4.2 Entrant/Exit Impact Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Antibiotic Resistant Infection Revenue Trends by Type

4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.1.2 Global Revenue Market Share by Type (2020-2031)

4.2 Key Product Attributes and Differentiation

4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.3.1 High-Growth Niches and Adoption Drivers

4.3.2 Profitability Hotspots and Cost Drivers

4.3.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Antibiotic Resistant Infection Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.1.2 Revenue Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2020-2031)

6.2 North America Key Players Revenue in 2024

6.3 North America Antibiotic Resistant Infection Market Size by Type (2020-2031)

6.4 North America Antibiotic Resistant Infection Market Size by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Antibiotic Resistant Infection Market Size by Country

6.6.1 North America Revenue Trends by Country

6.6.2 US

6.6.3 Canada

6.6.4 Mexico

7 Europe

7.1 Europe Market Size (2020-2031)

7.2 Europe Key Players Revenue in 2024

7.3 Europe Antibiotic Resistant Infection Market Size by Type (2020-2031)

7.4 Europe Antibiotic Resistant Infection Market Size by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Antibiotic Resistant Infection Market Size by Country

7.6.1 Europe Revenue Trends by Country

7.6.2 Germany

7.6.3 France

7.6.4 U.K.

7.6.5 Italy

7.6.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2020-2031)

8.2 Asia-Pacific Key Players Revenue in 2024

8.3 Asia-Pacific Antibiotic Resistant Infection Market Size by Type (2020-2031)

8.4 Asia-Pacific Antibiotic Resistant Infection Market Size by Application (2020-2031)

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Asia-Pacific Antibiotic Resistant Infection Market Size by Region

8.6.1 Asia-Pacific Revenue Trends by Region

8.7 China

8.8 Japan

8.9 South Korea

8.10 Australia

8.11 India

8.12 Southeast Asia

8.12.1 Indonesia

8.12.2 Vietnam

8.12.3 Malaysia

8.12.4 Philippines

8.12.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2020-2031)

9.2 Central and South America Key Players Revenue in 2024

9.3 Central and South America Antibiotic Resistant Infection Market Size by Type (2020-2031)

9.4 Central and South America Antibiotic Resistant Infection Market Size by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Antibiotic Resistant Infection Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2020-2031)

10.2 Middle East and Africa Key Players Revenue in 2024

10.3 Middle East and Africa Antibiotic Resistant Infection Market Size by Type (2020-2031)

10.4 Middle East and Africa Antibiotic Resistant Infection Market Size by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Antibiotic Resistant Infection Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Israel

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Pfizer

11.1.1 Pfizer Corporation Information

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Antibiotic Resistant Infection Product Features and Attributes

11.1.4 Pfizer Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.1.5 Pfizer Antibiotic Resistant Infection Revenue by Product in 2024

11.1.6 Pfizer Antibiotic Resistant Infection Revenue by Application in 2024

11.1.7 Pfizer Antibiotic Resistant Infection Revenue by Geographic Area in 2024

11.1.8 Pfizer Antibiotic Resistant Infection SWOT Analysis

11.1.9 Pfizer Recent Developments

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Corporation Information

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Antibiotic Resistant Infection Product Features and Attributes

11.2.4 Johnson & Johnson Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.2.5 Johnson & Johnson Antibiotic Resistant Infection Revenue by Product in 2024

11.2.6 Johnson & Johnson Antibiotic Resistant Infection Revenue by Application in 2024

11.2.7 Johnson & Johnson Antibiotic Resistant Infection Revenue by Geographic Area in 2024

11.2.8 Johnson & Johnson Antibiotic Resistant Infection SWOT Analysis

11.2.9 Johnson & Johnson Recent Developments

11.3 Merck & Co., Inc.

11.3.1 Merck & Co., Inc. Corporation Information

11.3.2 Merck & Co., Inc. Business Overview

11.3.3 Merck & Co., Inc. Antibiotic Resistant Infection Product Features and Attributes

11.3.4 Merck & Co., Inc. Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.3.5 Merck & Co., Inc. Antibiotic Resistant Infection Revenue by Product in 2024

11.3.6 Merck & Co., Inc. Antibiotic Resistant Infection Revenue by Application in 2024

11.3.7 Merck & Co., Inc. Antibiotic Resistant Infection Revenue by Geographic Area in 2024

11.3.8 Merck & Co., Inc. Antibiotic Resistant Infection SWOT Analysis

11.3.9 Merck & Co., Inc. Recent Developments

11.4 GSK

11.4.1 GSK Corporation Information

11.4.2 GSK Business Overview

11.4.3 GSK Antibiotic Resistant Infection Product Features and Attributes

11.4.4 GSK Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.4.5 GSK Antibiotic Resistant Infection Revenue by Product in 2024

11.4.6 GSK Antibiotic Resistant Infection Revenue by Application in 2024

11.4.7 GSK Antibiotic Resistant Infection Revenue by Geographic Area in 2024

11.4.8 GSK Antibiotic Resistant Infection SWOT Analysis

11.4.9 GSK Recent Developments

11.5 Roche

11.5.1 Roche Corporation Information

11.5.2 Roche Business Overview

11.5.3 Roche Antibiotic Resistant Infection Product Features and Attributes

11.5.4 Roche Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.5.5 Roche Antibiotic Resistant Infection Revenue by Product in 2024

11.5.6 Roche Antibiotic Resistant Infection Revenue by Application in 2024

11.5.7 Roche Antibiotic Resistant Infection Revenue by Geographic Area in 2024

11.5.8 Roche Antibiotic Resistant Infection SWOT Analysis

11.5.9 Roche Recent Developments

11.6 AbbVie

11.6.1 AbbVie Corporation Information

11.6.2 AbbVie Business Overview

11.6.3 AbbVie Antibiotic Resistant Infection Product Features and Attributes

11.6.4 AbbVie Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.6.5 AbbVie Recent Developments

11.7 AstraZeneca

11.7.1 AstraZeneca Corporation Information

11.7.2 AstraZeneca Business Overview

11.7.3 AstraZeneca Antibiotic Resistant Infection Product Features and Attributes

11.7.4 AstraZeneca Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.7.5 AstraZeneca Recent Developments

11.8 Bayer AG

11.8.1 Bayer AG Corporation Information

11.8.2 Bayer AG Business Overview

11.8.3 Bayer AG Antibiotic Resistant Infection Product Features and Attributes

11.8.4 Bayer AG Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.8.5 Bayer AG Recent Developments

11.9 Teva Pharmaceutical

11.9.1 Teva Pharmaceutical Corporation Information

11.9.2 Teva Pharmaceutical Business Overview

11.9.3 Teva Pharmaceutical Antibiotic Resistant Infection Product Features and Attributes

11.9.4 Teva Pharmaceutical Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.9.5 Teva Pharmaceutical Recent Developments

11.10 Sanofi

11.10.1 Sanofi Corporation Information

11.10.2 Sanofi Business Overview

11.10.3 Sanofi Antibiotic Resistant Infection Product Features and Attributes

11.10.4 Sanofi Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.10.5 Company Ten Recent Developments

11.11 Novartis

11.11.1 Novartis Corporation Information

11.11.2 Novartis Business Overview

11.11.3 Novartis Antibiotic Resistant Infection Product Features and Attributes

11.11.4 Novartis Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.11.5 Novartis Recent Developments

11.12 Lupin

11.12.1 Lupin Corporation Information

11.12.2 Lupin Business Overview

11.12.3 Lupin Antibiotic Resistant Infection Product Features and Attributes

11.12.4 Lupin Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.12.5 Lupin Recent Developments

11.13 Advacare Pharma

11.13.1 Advacare Pharma Corporation Information

11.13.2 Advacare Pharma Business Overview

11.13.3 Advacare Pharma Antibiotic Resistant Infection Product Features and Attributes

11.13.4 Advacare Pharma Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.13.5 Advacare Pharma Recent Developments

11.14 Validus Pharmaceuticals

11.14.1 Validus Pharmaceuticals Corporation Information

11.14.2 Validus Pharmaceuticals Business Overview

11.14.3 Validus Pharmaceuticals Antibiotic Resistant Infection Product Features and Attributes

11.14.4 Validus Pharmaceuticals Antibiotic Resistant Infection Revenue and Gross Margin (2020-2025)

11.14.5 Validus Pharmaceuticals Recent Developments

12 Antibiotic Resistant InfectionIndustry Chain Analysis

12.1 Antibiotic Resistant Infection Industry Chain

12.2 Upstream Analysis

12.2.1 Upstream Key Suppliers

12.3 Middlestream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Antibiotic Resistant Infection Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Antibiotic Resistant Infection Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Validus Pharmaceuticals

List of Tables

Table 1. Global Antibiotic Resistant Infection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Antibiotic Resistant Infection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Antibiotic Resistant Infection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Antibiotic Resistant Infection Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Antibiotic Resistant Infection Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Antibiotic Resistant Infection Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Antibiotic Resistant Infection Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Antibiotic Resistant Infection by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibiotic Resistant Infection as of 2024)

Table 11. Global Antibiotic Resistant Infection Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Antibiotic Resistant Infection Companies Headquarters

Table 13. Global Antibiotic Resistant Infection Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Antibiotic Resistant Infection Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Antibiotic Resistant Infection Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Antibiotic Resistant Infection Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Antibiotic Resistant Infection Revenue by Application (2026-2031) & (US$ Million)

Table 21. Antibiotic Resistant Infection High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Antibiotic Resistant Infection Growth Accelerators and Market Barriers

Table 25. North America Antibiotic Resistant Infection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Antibiotic Resistant Infection Growth Accelerators and Market Barriers

Table 27. Europe Antibiotic Resistant Infection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Antibiotic Resistant Infection Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Antibiotic Resistant Infection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Antibiotic Resistant Infection Investment Opportunities and Key Challenges

Table 31. Central and South America Antibiotic Resistant Infection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Antibiotic Resistant Infection Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Antibiotic Resistant Infection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Pfizer Corporation Information

Table 35. Pfizer Description and Major Businesses

Table 36. Pfizer Product Features and Attributes

Table 37. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Pfizer Revenue Proportion by Product in 2024

Table 39. Pfizer Revenue Proportion by Application in 2024

Table 40. Pfizer Revenue Proportion by Geographic Area in 2024

Table 41. Pfizer Antibiotic Resistant Infection SWOT Analysis

Table 42. Pfizer Recent Developments

Table 43. Johnson & Johnson Corporation Information

Table 44. Johnson & Johnson Description and Major Businesses

Table 45. Johnson & Johnson Product Features and Attributes

Table 46. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Johnson & Johnson Revenue Proportion by Product in 2024

Table 48. Johnson & Johnson Revenue Proportion by Application in 2024

Table 49. Johnson & Johnson Revenue Proportion by Geographic Area in 2024

Table 50. Johnson & Johnson Antibiotic Resistant Infection SWOT Analysis

Table 51. Johnson & Johnson Recent Developments

Table 52. Merck & Co., Inc. Corporation Information

Table 53. Merck & Co., Inc. Description and Major Businesses

Table 54. Merck & Co., Inc. Product Features and Attributes

Table 55. Merck & Co., Inc. Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Merck & Co., Inc. Revenue Proportion by Product in 2024

Table 57. Merck & Co., Inc. Revenue Proportion by Application in 2024

Table 58. Merck & Co., Inc. Revenue Proportion by Geographic Area in 2024

Table 59. Merck & Co., Inc. Antibiotic Resistant Infection SWOT Analysis

Table 60. Merck & Co., Inc. Recent Developments

Table 61. GSK Corporation Information

Table 62. GSK Description and Major Businesses

Table 63. GSK Product Features and Attributes

Table 64. GSK Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. GSK Revenue Proportion by Product in 2024

Table 66. GSK Revenue Proportion by Application in 2024

Table 67. GSK Revenue Proportion by Geographic Area in 2024

Table 68. GSK Antibiotic Resistant Infection SWOT Analysis

Table 69. GSK Recent Developments

Table 70. Roche Corporation Information

Table 71. Roche Description and Major Businesses

Table 72. Roche Product Features and Attributes

Table 73. Roche Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Roche Revenue Proportion by Product in 2024

Table 75. Roche Revenue Proportion by Application in 2024

Table 76. Roche Revenue Proportion by Geographic Area in 2024

Table 77. Roche Antibiotic Resistant Infection SWOT Analysis

Table 78. Roche Recent Developments

Table 79. AbbVie Corporation Information

Table 80. AbbVie Description and Major Businesses

Table 81. AbbVie Product Features and Attributes

Table 82. AbbVie Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. AbbVie Recent Developments

Table 84. AstraZeneca Corporation Information

Table 85. AstraZeneca Description and Major Businesses

Table 86. AstraZeneca Product Features and Attributes

Table 87. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. AstraZeneca Recent Developments

Table 89. Bayer AG Corporation Information

Table 90. Bayer AG Description and Major Businesses

Table 91. Bayer AG Product Features and Attributes

Table 92. Bayer AG Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Bayer AG Recent Developments

Table 94. Teva Pharmaceutical Corporation Information

Table 95. Teva Pharmaceutical Description and Major Businesses

Table 96. Teva Pharmaceutical Product Features and Attributes

Table 97. Teva Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Teva Pharmaceutical Recent Developments

Table 99. Sanofi Corporation Information

Table 100. Sanofi Description and Major Businesses

Table 101. Sanofi Product Features and Attributes

Table 102. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. Sanofi Recent Developments

Table 104. Novartis Corporation Information

Table 105. Novartis Description and Major Businesses

Table 106. Novartis Product Features and Attributes

Table 107. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. Novartis Recent Developments

Table 109. Lupin Corporation Information

Table 110. Lupin Description and Major Businesses

Table 111. Lupin Product Features and Attributes

Table 112. Lupin Revenue (US$ Million) and Gross Margin (2020-2025)

Table 113. Lupin Recent Developments

Table 114. Advacare Pharma Corporation Information

Table 115. Advacare Pharma Description and Major Businesses

Table 116. Advacare Pharma Product Features and Attributes

Table 117. Advacare Pharma Revenue (US$ Million) and Gross Margin (2020-2025)

Table 118. Advacare Pharma Recent Developments

Table 119. Validus Pharmaceuticals Corporation Information

Table 120. Validus Pharmaceuticals Description and Major Businesses

Table 121. Validus Pharmaceuticals Product Features and Attributes

Table 122. Validus Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 123. Validus Pharmaceuticals Recent Developments

Table 124. Raw Materials Key Suppliers

Table 125. Distributors List

Table 126. Market Trends and Market Evolution

Table 127. Market Drivers and Opportunities

Table 128. Market Challenges, Risks, and Restraints

Table 129. Research Programs/Design for This Report

Table 130. Key Data Information from Secondary Sources

Table 131. Key Data Information from Primary Sources

List of Figures

Figure 1. Antibiotic Resistant Infection Product Picture

Figure 2. Global Antibiotic Resistant Infection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Oral Product Picture

Figure 4. Parenteral Product Picture

Figure 5. Global Antibiotic Resistant Infection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Hospital Pharmacies

Figure 7. Retail Pharmacies

Figure 8. Other

Figure 9. Antibiotic Resistant Infection Report Years Considered

Figure 10. Global Antibiotic Resistant Infection Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 12. Global Antibiotic Resistant Infection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Antibiotic Resistant Infection Revenue Market Share by Region (2020-2031)

Figure 14. Global Antibiotic Resistant Infection Revenue Market Share Ranking (2024)

Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 16. Oral Revenue Market Share by Player in 2024

Figure 17. Parenteral Revenue Market Share by Player in 2024

Figure 18. Global Antibiotic Resistant Infection Revenue Market Share by Type (2020-2031)

Figure 19. Global Antibiotic Resistant Infection Revenue Market Share by Application (2020-2031)

Figure 20. North America Antibiotic Resistant Infection Revenue YoY (2020-2031) & (US$ Million)

Figure 21. North America Top 5 Players Antibiotic Resistant Infection Revenue (US$ Million) in 2024

Figure 22. North America Antibiotic Resistant Infection Revenue (US$ Million) by Type (2020 - 2031)

Figure 23. North America Antibiotic Resistant Infection Revenue (US$ Million) by Application (2020-2031)

Figure 24. US Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 25. Canada Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 26. Mexico Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 27. Europe Antibiotic Resistant Infection Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Europe Top 5 Players Antibiotic Resistant Infection Revenue (US$ Million) in 2024

Figure 29. Europe Antibiotic Resistant Infection Revenue (US$ Million) by Type (2020-2031)

Figure 30. Europe Antibiotic Resistant Infection Revenue (US$ Million) by Application (2020-2031)

Figure 31. Germany Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 32. France Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 33. U.K. Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 34. Italy Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 35. Russia Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Antibiotic Resistant Infection Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Top 8 Players Antibiotic Resistant Infection Revenue (US$ Million) in 2024

Figure 38. Asia-Pacific Antibiotic Resistant Infection Revenue (US$ Million) by Type (2020-2031)

Figure 39. Asia-Pacific Antibiotic Resistant Infection Revenue (US$ Million) by Application (2020-2031)

Figure 40. Indonesia Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 41. Japan Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 42. South Korea Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 43. Australia Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 44. India Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 45. Indonesia Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 46. Vietnam Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 47. Malaysia Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 48. Philippines Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 49. Singapore Antibiotic Resistant Infection Revenue (2020-2031) & (US$ Million)

Figure 50. Central and South America Antibiotic Resistant Infection Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Central and South America Top 5 Players Antibiotic Resistant Infection Revenue (US$ Million) in 2024

Figure 52. Central and South America Antibiotic Resistant Infection Revenue (US$ Million) by Type (2020-2031)

Figure 53. Central and South America Antibiotic Resistant Infection Revenue (US$ Million) by Application (2020-2031)

Figure 54. Brazil Antibiotic Resistant Infection Revenue (2020-2025) & (US$ Million)

Figure 55. Argentina Antibiotic Resistant Infection Revenue (2020-2025) & (US$ Million)

Figure 56. Middle East and Africa Antibiotic Resistant Infection Revenue YoY (2020-2031) & (US$ Million)

Figure 57. Middle East and Africa Top 5 Players Antibiotic Resistant Infection Revenue (US$ Million) in 2024

Figure 58. South America Antibiotic Resistant Infection Revenue (US$ Million) by Type (2020-2031)

Figure 59. Middle East and Africa Antibiotic Resistant Infection Revenue (US$ Million) by Application (2020-2031)

Figure 60. GCC Countries Antibiotic Resistant Infection Revenue (2020-2025) & (US$ Million)

Figure 61. Israel Antibiotic Resistant Infection Revenue (2020-2025) & (US$ Million)

Figure 62. Egypt Antibiotic Resistant Infection Revenue (2020-2025) & (US$ Million)

Figure 63. South Africa Antibiotic Resistant Infection Revenue (2020-2025) & (US$ Million)

Figure 64. Antibiotic Resistant Infection Industry Chain Mapping

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-4U20267

Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Global Anticoccidial Solutions Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-16R16865

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Bacterial Enteric Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-3F17301

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Whooping Cough Vaccination Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-4B20221

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Antibiotic Resistant Infection Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: October 2025

Report Code: QYRE-Auto-25Z17617

Global Antibiotic Resistant Infection Market Outlook, In‑Depth Analysis & Forecast to 2031

FEATURED COMPANIES

Antibiotic Resistant Infection Market

Report Includes:

Scope of Antibiotic Resistant Infection Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Antibiotic Resistant Infection Market report?

What are the Application segmentation covered in the Antibiotic Resistant Infection Market report?

What are the Type segmentation covered in the Antibiotic Resistant Infection Market report?

FEATURED COMPANIES

RELATED REPORTS